Follow
Sean Yamada-Hunter
Sean Yamada-Hunter
Postdoctoral Fellow, Stanford University
Verified email at stanford.edu
Title
Cited by
Cited by
Year
Scl represses cardiomyogenesis in prospective hemogenic endothelium and endocardium
B Van Handel, A Montel-Hagen, R Sasidharan, H Nakano, R Ferrari, ...
Cell 150 (3), 590-605, 2012
1822012
Enhanced safety and efficacy of protease-regulated CAR-T cell receptors
L Labanieh, RG Majzner, D Klysz, E Sotillo, CJ Fisher, JG Vilches-Moure, ...
Cell 185 (10), 1745-1763. e22, 2022
1472022
Cell-binding assays for determining the affinity of protein–protein interactions: technologies and considerations
SA Hunter, JR Cochran
Methods in enzymology 580, 21-44, 2016
842016
An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA
N Mehta, S Maddineni, RL Kelly, RB Lee, SA Hunter, JL Silberstein, ...
Scientific reports 10 (1), 15171, 2020
482020
An engineered ligand trap inhibits leukemia inhibitory factor as pancreatic cancer treatment strategy
SA Hunter, BJ McIntosh, Y Shi, RAP Sperberg, C Funatogawa, ...
Communications Biology 4 (1), 452, 2021
272021
Development of a protease biosensor based on a dimerization-dependent red fluorescent protein
AC Mitchell, SC Alford, SA Hunter, D Kannan, RA Parra Sperberg, ...
ACS chemical biology 13 (1), 66-72, 2018
242018
Engineered CD47 protects T cells for enhanced antitumour immunity
SA Yamada-Hunter, J Theruvath, BJ McIntosh, KA Freitas, F Lin, ...
Nature, 1-9, 2024
202024
Engineering a potent inhibitor of matriptase from the natural hepatocyte growth factor activator inhibitor type-1 (HAI-1) protein
AC Mitchell, D Kannan, SA Hunter, RAP Sperberg, CH Chang, ...
Journal of Biological Chemistry 293 (14), 4969-4980, 2018
112018
Stem cell factor lifted as a promising clinical target for cancer therapy
Y Shi, S Hunter, T Hunter
Molecular cancer therapeutics 18 (8), 1337-1340, 2019
72019
Directed evolution of genetically encoded LYTACs for cell-mediated delivery
JL Yang, SA Yamada-Hunter, L Labanieh, E Sotillo, JS Cheah, ...
Proceedings of the National Academy of Sciences 121 (13), e2320053121, 2024
42024
An engineered NKp46 antibody for construction of multi-specific NK cell engagers
RB Lee, S Maddineni, M Landry, C Diaz, A Tashfeen, SA Yamada-Hunter, ...
Protein Engineering, Design and Selection 37, gzae013, 2024
12024
Abstract B052: IKAROS mediates antigen escape following CD19-or CD22-targeted immunotherapies in r/r B-ALL
P Domizi, J Sarno, A Jager, M Merchant, K Pacheco, S Yamada-Hunter, ...
Cancer Research 84 (17_Supplement), B052-B052, 2024
2024
Soluble leukemia inhibitory factor receptor polypeptides and methods of using same for inhibiting leukemia inhibitory factor activity
S Yamada-Hunter, JR Cochran
US Patent 12,049,490, 2024
2024
IKAROS facilitates antigen escape in the face of CD19-and CD22-targeted therapies for B-cell acute lymphoblastic leukemia
P Domizi, J Sarno, A Jager, M Merchant, KZB Pacheco, ...
bioRxiv, 2024.11. 01.621347, 2024
2024
An engineered interleukin‐11 decoy cytokine inhibits receptor signaling and proliferation in lung adenocarcinoma
BJ McIntosh, GG Hartmann, SA Yamada‐Hunter, P Liu, CF Williams, ...
Bioengineering & Translational Medicine 8 (6), e10573, 2023
2023
Harnessing macrophages, while protecting T cells, enhances anti-tumor efficacy
SA Yamada-Hunter, J Theruvath, MT Radosevich, BJ McIntosh, ...
Cancer Research 83 (7_Supplement), 5741-5741, 2023
2023
The system can't perform the operation now. Try again later.
Articles 1–16